Sanofi kicks off year with robust growth driven by Specialty Care and Vaccines

Sanofi has reported IFRS net sales of €8,648m, which is a 11.1% positive change. In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement, which was €1,795m, up 4.2% from the same period last year. 

Sanofi has reported first-quarter Pharmaceuticals sales increased 7.4% to €7,864 million. At constant structure, Pharmaceuticals sales were up 2.6% driven by Multiple Sclerosis, CHC, Rare Disease, Oncology and Cardiovascular franchises.

The company saw a minus from Diabetes and Cardiovascular sales, which was a 7.7% drop to $1,419,and Cerezyme also fell short nearly 5% from the last year’s line.

Multiple sclerosis franchise products Aubagio and Lemtrada had a total increase in sales of 32.4%, while the oncology franchise had a total growth of 12.8%, with only Zaltrap seeing reduced sales of almost 6%. Mozobil had growth of 11.4%.

The largest drop was seen in diabetes franchise sales, with most products dropping in sales, apart from Toujeo (up 78.6%) and Apidra and Amaryl with 14.1 and 5.7% respectively. Total diabetel sales were €1,663, which is a 6% drop.

Total established Rx products were mainly unchanged with 0.6% up. Aprovel/Avapro saw 13% raise in sales, while Allegra dropped 13.3%.

Vaccines net sales saw increase of total 22.2%, mainly driven up with increased sales of Influenza vaccines including Vaxigrip and Fluzone, Polio/Pertussis/Hib vaccines and travel and other endemic vcaccines.

Sanofi Chief Executive Officer, Olivier Brandicourt, said that the company has started the year with robust growth driven by Specialty Care and Vaccines as well as good performance in Emerging Markets.

“Our top line in the first quarter also benefited from the integration of the Boehringer Ingelheim CHC and European vaccine businesses. At the same time, the simplified organization continues to contribute to Sanofi’s financial performance,” Said Brandicourt.

He added that the U.S. launch of Dupixent for moderate-to-severe atopic dermatitis marks a key innovation milestone on the companies goal for its new immunology franchise. “We are excited to bring this highly innovative medicine to patients suffering from this devastating disease,” the CEO said.